Jeffrey Eisele, the Chief Development Officer at Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), a $3.8 billion market cap biopharmaceutical company, recently sold a portion of his holdings in the ...
Some results have been hidden because they may be inaccessible to you